About Opexa Therapeutics (NASDAQ:ACER)
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ACER
- CUSIP: N/A
- Web: www.opexatherapeutics.com
- Market Cap: $13.17 million
- Outstanding Shares: 739,000
- 50 Day Moving Avg: $14.05
- 200 Day Moving Avg: $9.26
- 52 Week Range: $5.18 - $36.76
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Return on Equity: -157.46%
- Return on Assets: -106.61%
- Current Ratio: 5.50%
- Quick Ratio: 5.50%
- Average Volume: 128,811 shs.
- Beta: 2.28
Frequently Asked Questions for Opexa Therapeutics (NASDAQ:ACER)
What is Opexa Therapeutics' stock symbol?
Opexa Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
How were Opexa Therapeutics' earnings last quarter?
Opexa Therapeutics, Inc. (NASDAQ:ACER) issued its quarterly earnings results on Friday, May, 12th. The company reported ($0.12) earnings per share for the quarter. View Opexa Therapeutics' Earnings History.
Who are some of Opexa Therapeutics' key competitors?
Some companies that are related to Opexa Therapeutics include Pain Therapeutics (PTIE), Midatech Pharma PLC (MTPH), Xenetic Biosciences (XBIO), Heat Biologics (HTBX), Cerulean Pharma (DARE), Ritter Pharmaceuticals (RTTR), Anthera Pharmaceuticals (ANTH), Biopharmx Corp (BPMX), Biopharmx Corp (BPMX), Biopharmx Corp (BPMX), Evgen Pharma PLC (EVG), Proteome Sciences plc (PRM), Kitov Pharmaceuticals Holdings (KTOV), Bio Blast Pharma (ORPN), ValiRx Plc (VAL), Ariad Pharmaceuticals (ARIA), Auspex Pharmaceuticals (ASPX) and Biotie Therapies Corp (BITI).
Who are Opexa Therapeutics' key executives?
Opexa Therapeutics' management team includes the folowing people:
- Christopher Schelling, President, Chief Executive Officer, Director
- Harry S. Palmin, Chief Financial Officer
- William T. Andrews, Chief Medical Officer
- Jason Amello, Director
- Stephen J. Aselage, Director
- Hubert Birner, Director
- John M. Dunn, Director
- Michelle Griffin, Director
How do I buy Opexa Therapeutics stock?
Shares of Opexa Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Opexa Therapeutics' stock price today?
MarketBeat Community Rating for Opexa Therapeutics (NASDAQ ACER)MarketBeat's community ratings are surveys of what our community members think about Opexa Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Opexa Therapeutics stock can currently be purchased for approximately $18.57.
Earnings History for Opexa Therapeutics (NASDAQ:ACER)Earnings History by Quarter for Opexa Therapeutics (NASDAQ ACER)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2016||Q3 2016||($0.25)||($0.28)||$0.73 million||View||N/A|
|8/11/2016||Q216||($0.23)||($0.30)||$0.73 million||$0.73 million||View||Listen|
|5/12/2016||Q116||($0.35)||($0.31)||$0.73 million||$0.73 million||View||Listen|
|3/15/2016||Q415||($0.50)||($2.05)||$0.73 million||$0.73 million||View||Listen|
|11/10/2015||Q315||($2.48)||($0.42)||$0.73 million||$0.73 million||View||N/A|
|11/6/2014||($0.14)||($0.12)||$0.30 million||$0.31 million||View||N/A|
|8/14/2014||Q214||($0.13)||($0.15)||$0.30 million||$0.31 million||View||N/A|
|5/14/2014||Q114||($0.13)||($0.13)||$0.22 million||$0.35 million||View||N/A|
Earnings Estimates for Opexa Therapeutics (NASDAQ:ACER)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Opexa Therapeutics (NASDAQ:ACER)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Opexa Therapeutics (NASDAQ:ACER)
Insider Ownership Percentage: 6.88%Insider Trades by Quarter for Opexa Therapeutics (NASDAQ:ACER)
Institutional Ownership Percentage: 36.35%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/18/2016||Timothy C Barabe||Director||Sell||14,914||$0.55||$8,202.70|| |
|9/17/2014||Timothy C Barabe||Director||Buy||10,000||$1.15||$11,500.00|| |
|9/16/2014||Neil K Warma||CEO||Buy||10,000||$1.11||$11,100.00|| |
|12/18/2013||Karthik Radhakrishnan||CFO||Buy||8,000||$1.70||$13,600.00|| |
|12/18/2013||Scott B Seaman||Director||Buy||30,000||$1.70||$51,000.00|| |
|8/8/2013||Karthik Radhakrishnan||CFO||Buy||50,000||$1.50||$75,000.00|| |
Headline Trends for Opexa Therapeutics (NASDAQ:ACER)
Latest Headlines for Opexa Therapeutics (NASDAQ:ACER)
Loading headlines, please wait.
Opexa Therapeutics (ACER) Chart for Tuesday, October, 24, 2017